A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Recruiting · NCT06872112 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Artesunate
What this trial is about
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
Who can take part
Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Each participant must meet the following criteria to be enrolled in this study:
- Adults aged 18 to 75 years.
- WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.
Exclusion criteria
- Participants who meet any of the following criteria will be excluded from the study.
- Participants with serious concomitant morbidity per investigator assessment.
Where it is running
1 location listed across 1 US state.
- Stanford University - Stanford, California, United States